|
Cyclic
adenosine monophosphate (cAMP) serves as a second messenger in
multiple cell signaling pathways. As well, cAMP stimulates protein
kinase A-mediated phosphorylation of the cAMP-response element
binding protein (CREB) family at a conserved serine (Ser-133 in
CREB1), which in turn leads to the recruitment of coactivators,
including CREB-binding protein (CBP)/p300, TORC and TAFII4.
Phospho-CREB (P-CREB) binds cAMP-response elements (CREs) in gene
promoters, and thereby coordinates with other transcription factors
to recruit RNA polymerase II to the promoters and stimulate
transcription of target genes.
Zhang
and colleagues used genome-wide approaches, including microarray
analyses and chromatin immunoprecipitation (ChIP) assays, to
characterize the target genes and regulation of CREB activity in
different human tissues. They started by searching for full CREs
(TGACGTCA) and half-CREs (TGACG/CGTCA) that were conserved in human,
mouse, and rat genome alignments. Promoters were defined as 3kb
upstream to 300 bp downstream of annotated transcription start sites;
downstream (within 300 bp) TATA boxes were sought for all CREs that
were identified in promoter sequences. In the human genome 10,447
CREs and 740,390 half-CREs were found, with the majority of conserved
CREs occurring within 200bp of the transcription start site.
Combining 3 independent algorithms, the authors identified 4 084
putative CREB target genes, of which 1 518 also contained TATA boxes.
CREB target genes were mostly transcription factors (38%), followed
by genes involved in metabolic control, cell-cycle regulation, and
regulated secretion.
The
authors proceeded to investigate mechanisms of regulation of CREB
binding that may explain the tissue specificity of CREB target gene
profiles. About 3000 promoters (17% of protein-coding genes) were
found to be CREB occupied in vivo.
CpG methylation at the CRE inhibits CREB binding, and some CREs were
found to be always unmethylated (ie, CREB-responsive), some
universally methylated (ie, silenced genes), and others methylated
only in certain cell types. Levels of P-CREB were low in resting
conditions, but increased markedly within one hour of exposure to
forskolin, a cAMP agonist; changes in P-CREB levels did not differ
between cAMP inducible versus noninducible genes, so differential
CREB phosphorylation does not construe a mechanism for tissue
specificity of target gene profiles. Forskolin induced appoximately
100 genes in 3 different cell types tested, though the sets were
mostly distinct. Likewise, cAMP stimulated growth factor genes and
antiapoptotic genes in cultured human islets, in contrast to primary
hepatocytes, where it stimulated genes involved in fasting glucose
and lipid metabolism. Recruitment of CBP and other CREB regulatory
partners to promoters by cAMP or forskolin was another mechanism
identified for tissue specificity of the target gene profiles.
Zhang X, Odom DT, Koo S-H, et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci. 2005;102:4459-4464.
Editor’s
Comment: The power of genome-wide bioinformatics makes it now
feasible to study the response patterns to such fundamental signaling
mechanisms like the cAMP pathway. I refer the reader to the databases
posted by the authors as excellent reference tools. For example, at
http://natural.salk.edu/CREB,
one can search human, mouse and rat genes of interest to see if/where
they have CREB binding and inducibility by cAMP in various tissues.
cAMP is an important second messenger for multiple water-soluble
hormones that bind cell surface receptors. Such hormones include:
somatostatin, chorionic gonadotropin (HCG), lipotropin (LPH),
melanocyte stimulating hormone (MSH), adrenocorticotrophic hormone
(ACTH), follicle-stimulating hormone (FSH), luteinizing hormone (LH),
thyroid stimulating hormone (TSH), antidiuretic hormone (ADH),
parathyroid hormone (PTH), calcitonin and glucagon. Various reviews
of cAMP signaling in the endocrine system are listed below.1-7
Adda Grimberg, MD
References - (linked to )
-
Granner
DK. Hormonal Action. In: Becker KL, ed. Principles and Practice
of Endocrinology and Metabolism, 2nd ed.
Philadelphia, PA: Lippincott ;1995:20-34.
-
Richards
JS. New signaling pathways for hormones and cyclic adenosine
3',5'-monophosphate action in endocrine cells. Molec Endocrinol.
2001;15:209-18.
-
Montminy
M, Brindle P, Arias J, Ferreri K, Armstrong R. Regulation of
somatostatin gene transcription by cAMP. Adv Pharmacol.
1996;36:1-13.
-
Weiner
RI, Charles A. Regulation of gonadotropin-releasing hormone release
by cyclic AMP signalling pathways. Growth Horm Igf Res.
2001;11(Suppl A):S9-15.
-
Dremier
S, Coulonval K, Perpete S, et al. The role of cyclic AMP and its
effect on protein kinase A in the mitogenic action of thyrotropin on
the thyroid cell. Ann NY Acad Sci. 2002;968:106-121.
-
Klussmann
E, Rosenthal W. Role and identification of protein kinase A
anchoring proteins in vasopressin-mediated aquaporin-2
translocation. Kidney Internatl. 2001;60:446-449.
-
Nesher
R, Anteby E, Yedovizky M, Warwar N, Kaiser N, Cerasi E. Beta-cell
protein kinases and the dynamics of the insulin response to glucose.
Diabetes. 2002;51(suppl 1):S68-S73.
|